In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inovio Pharmaceuticals (INO), with a price target of $13. The company’s shares closed yesterday at $2.98.
Selvaraju observed:
“Our 12-month price target is derived from a market value of the firm at $1.38B, which includes a discounted cash flow based asset value of $1.45B for 15% discount rate, 2% terminal growth rate, 80% probability of success, excluding $78.5M in debt and assuming 105M shares outstanding at the end of 1Q20.”
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 4.2% and a 33.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $11.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.30 and a one-year low of $2.15. Currently, Inovio Pharmaceuticals has an average volume of 1.1M.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
